Nephrocare Health Services Expands in Kazakhstan

Transaction value: Rs 11.64 crore (KZT 561.66 million) for a 100% stake acquisition.

Reader Takeaway: Acquisition boosts international footprint; watch for smooth regulatory integration in the Kazakh market.

What just happened

Nephrocare Health Services Ltd has announced the acquisition of 100% interest in Dialysis Center Almaty LLP, a company based in Kazakhstan, through its overseas step-down subsidiary. The total cash consideration for the deal is approximately Rs 11.64 crore.

Why this matters

This acquisition is a strategic move to scale Nephrocare’s specialized dialysis operations beyond Indian borders. The target entity operates 34 dialysis machines and has shown steady revenue growth, reporting a turnover of approximately Rs 10.93 crore in calendar year 2025. Adding this operational unit strengthens the company's international service infrastructure.

Regulatory and Closing Conditions

The agreement is currently subject to specific conditions precedent, including compliance with Kazakh legal formalities. A key requirement is the state re-registration of the target entity following the transfer of interest to reflect the change in ownership.

Governance

Nephrocare Health Services has clarified that this is an arm's length transaction and does not fall under related party transactions. No promoters or group entities hold any interest in the target or the selling parties.

What to track next

Investors should monitor for the completion of the state re-registration process in Kazakhstan and the formal closing of the deal. The company’s ability to integrate these operations into their existing service model will determine the long-term ROI of this expansion.